STP 144G
Alternative Names: STP-144GLatest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator Sirnaomics
- Class Peptide drug conjugates; Small interfering RNA
- Mechanism of Action Complement factor B modulators; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Immunological disorders
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Immunological-disorders in USA (SC)
- 28 Mar 2024 Sirnaomics announces intention to file an IND application for STP 144G in the US in 2025
- 26 Aug 2022 Sirnaomics plans a clinical trial for Immunological disorders in second half of 2023